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Microbiology, Vall d’Hebron University Hospital, PROSICS Barcelona, Barcelona, SpainAbstractReactivation of Chagas disease in the chronic phase may occur when immunosuppression is established, sometimes resulting in high
parasitaemia and severe clinical manifestations such as meningitis and meningoencephalitis. Although this situation is being increasingly
described, there is still scarce information. This retrospective observational study was performed in three Tropical Medicine Units of
Barcelona (Spain) included in the International Health Programme of the Catalan Health Institute (PROSICS). The objective of the study
was to describe epidemiological, clinical, microbiological, prognostic and therapeutic data from patients with Chagas disease and any kind
of immunosuppressive condition attended in these three institutions from January 2007 to October 2014. From 1823 patients with
Chagas disease attending these three centres during the study period, 38 (2%) had some kind of immunosuppressive condition: 12
patients had human immunodeﬁciency virus infection, 8 patients had neoplasia, 4 patients underwent organ transplantation and 14
patients had an autoimmune disease. Eight (21.1%) patients had cardiac involvement, and six (15.8%) patients had gastrointestinal
involvement. Acute Trypanosoma cruzi infection was detected in two Spanish patients. Thirty-one (81.6%) patients received treatment
with benznidazole, of whom 17 (54.8%) had some kind of adverse event. No patient had a severe manifestation or reactivation of Chagas
disease. Patients with Chagas disease under immunosuppressive conditions are being increasingly described, especially in non-endemic
countries. More information about this topic is required and international consensus in the diagnosis, treatment and follow up of these
patients must be established to reduce the morbidity and mortality.
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E-mail: fmsalvad@vhebron.netIntroductionChagas disease is caused by Trypanosoma cruzi, a haemo-
ﬂagellate protozoa mostly transmitted through the faeces ofMicrobiol Infect 2015; 21: 854–860
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.033haematophagous triatomine vectors and congenitally from
mother to child. Other transmission routes include blood
transfusion and organ transplantation from infected donors,
transmission among injecting drug users and oral consumption
of contaminated food. The acute phase of the infection is either
asymptomatic or presents with non-speciﬁc symptoms (fever,
malaise, lymphadenopathy). After the acute phase, a subsequent
usually asymptomatic chronic stage (or indeterminate phase)
takes place over years; after 20–30 years, up to 30–40% of
patients develop the symptomatic chronic phase, with cardiac
and/or digestive involvement [1].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Salvador et al. Chagas disease and immunosuppression 855Reactivation in the chronic phase (detection of trypomasti-
gotes in blood and other body ﬂuids) may occur when immu-
nosuppression is established, sometimes resulting in high
parasitaemia, and severe clinical manifestations such asmeningitis
and encephalitis, acute myocarditis and skin lesions (panniculitis
and subcutaneous nodules) [2,3]. Human immunodeﬁciency
virus (HIV) infection has been the immunosuppressive condition
most described in patients with Chagas disease, and meningo-
encephalitis is the most prevalent clinical manifestation of Chagas
disease reactivation in HIV-infected patients [4,5]. Nevertheless,
Chagas disease reactivation is increasingly described in other
immunosuppressive conditions, such as organ transplantation,
neoplastic diseases and new immunosuppressive therapies [6,7].
Chagas disease was originally an endemic disease of Latin
America affecting rural and poor populations living in adobe
houses. However, the increase of population mobility during
last decades has lead to the spread of Chagas disease outside
endemic countries [8]. This fact has changed the clinical proﬁle
of patients with Chagas disease in non-endemic countries,
where patients may easily access newer therapies, including
those causing immunosuppression [9].
In this study we describe epidemiological and clinical data of
patients with Chagas disease with any kind of immunosup-
pression in a non-endemic country.Patients and methodsThis is a retrospective observational study performed in three
Tropical Medicine Units of Barcelona (Spain) included in the
International Health Programme of the Catalan Health Institute
(PROSICS): the Infectious Diseases Department of the Vall
d’Hebron University Hospital, the Special Programme for In-
fectious Diseases Vall d’Hebron-Drassanes and the North
Metropolitan International Health Unit. Data were collected
from clinical records of all patients diagnosed with Chagas
disease attended in these institutions from January 2007 to
October 2014. We included in the study all patients with
Chagas disease with any kind of immunosuppressive condition.
Epidemiological and clinical data were collected from all
included patients: age, gender, country of origin, time since
arrival to Spain, data related to Chagas disease (cardiac and
digestive involvement, severe clinical manifestation, microbio-
logical results, treatment and follow up), and data regarding the
immunosuppressive condition. Diagnosis of Chagas disease was
based upon the positivity of two different serological tests ac-
cording to WHO recommendations [10]; an ELISA with re-
combinant antigen (Bioelisa Chagas; Biokit, Lliçà d’Amunt,
Spain), and an ELISA with crude antigen (Ortho T. cruzi ELISA;
Johnson & Johnson, High Wycombe, UK or ELISA cruzi;Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologybioMérieux, Marcy-L’Étoile, France). When possible, peripheral
blood samples were collected and processed for T. cruzi PCR,
as described elsewhere [11]. All patients were offered to
receive treatment with benznidazole 5 mg/kg/day divided into
two or three doses for 60 days following the current WHO
recommendations [12]. We deﬁned reactivation of Chagas
disease during follow up as the positivity of T. cruzi PCR after
treatment completion.
The objective of the study was to describe epidemiological,
clinical, microbiological and therapeutic data from patients with
Chagas disease and any kind of immunosuppressive condition,
to contribute to increase the scarce information available in this
area, and to propose strategies to improve the management of
these patients.
The study protocol was approved by the Ethical Review
Board of the Vall d’Hebron University Hospital (Barcelona,
Spain). Procedures were performed in accordance with the
ethical standards laid down in the Declaration of Helsinki as
revised in 2000.
SPSS software for Windows (Version 19.0; SPSS Inc., Chi-
cago, IL, USA) was used for statistical analyses. Categorical data
are presented as absolute numbers and proportions, and
continuous variables are expressed as medians and ranges.ResultsOverall, 1823 patients with Chagas disease attended these
three centres included in PROSICS during the study period; of
these, 38 (2%) had some kind of immunosuppressive condition:
12 patients had HIV infection, 8 patients had neoplastic disease,
4 patients underwent organ transplantation, and 14 patients had
an autoimmune or rheumatic disease that required immuno-
suppressive therapy. The main characteristics of all patients are
described in Tables 1–4. The median age of patients was 37
(0–66) years and 25 (65.8%) were women. Most of them came
from Bolivia (35 patients, 92.1%), and the median time of
residence in our country at the time of Chagas disease diagnosis
was 6 (1–12) years. Eight (21.1%) patients had cardiac
involvement, all of them in the early asymptomatic cardiac stage
of the disease (stage I of the Kuschnir classiﬁcation), and six
(15.8%) patients had gastrointestinal involvement (three pa-
tients with dolichocolon, two patients with megacolon, and one
patient with low-grade oesophageal involvement). At the time
of Chagas disease diagnosis, 11 of 26 (42.3%) patients had a
positive T. cruzi PCR. No patient had a severe manifestation of
Chagas disease.
Acute T. cruzi infection was detected in two Spanish patients.
Patient 9 was a case of mother-to-child transmission of both
Chagas disease and HIV infection. She was a preterm baby dueand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 854–860
TABLE 2. Epidemiological and clinical characteristics of patients with Chagas disease and neoplastic disease
Patients
Country
of origin
Age
(years) Gender
Year of diagnosis
of CD CD clinical stage
Treatment
with BZD
Year of diagnosis
of neoplastic disease Neoplastic disease Immunosuppressive therapy
13 Bolivia 33 F 2010 Indeterminate stage No 2013 Uterine squamous carcinoma Cisplatin, radiotherapy, brachytherapy
14 Bolivia 49 M 2009 Indeterminate stage Yes 2009 HTLV-associated adult T-cell
leukaemia/lymphoma
R-CHOP, Alemtuzumab
15 Bolivia 43 F 2008 Indeterminate stage No 2000 Chronic myeloid leukaemia Imatinib, Dasatinib, Nilotinib
16 Bolivia 47 F 2013 CCC (KI) Yes 2013 Uterine squamous carcinoma Cisplatin, radiotherapy, brachytherapy
17 Bolivia 66 F 2013 Indeterminate stage Yes 2013 Splenic marginal zone lymphoma Rituximab
18 Bolivia 53 F 2009 Indeterminate stage Yes 2014 Breast adenocarcinoma —
19 Bolivia 48 F 2009 Indeterminate stage Yes 2009 Breast adenocarcinoma Docetaxel, Doxorubicine, Cyclophosphamide, radiotherapy
20 Bolivia 37 F 2011 Digestive involvement Yes 2014 Uterine squamous carcinoma —
Note: BZD, benznidazole; CD, Chagas disease; F, female; M, male; CCC (KI), chronic cardiac disease (Kuschnir stage I).
TABLE 1. Epidemiological and clinical characteristics of patients with Chagas disease and HIV infection
Patients
Country
of origin
Age
(years) Gender
Year of diagnosis
of CD CD clinical stage
Treatment
with BZD
Year of diagnosis
of HIV
Baseline CD4+ cell
count (cells/mm3)
Baseline HIV viral
load (copies/mL)
Opportunistic
infections
HAART when
receiving BZD
1 Bolivia 20 F 2008 Digestive involvement Yes 2008 230 14 000 None ABC, 3TC, EFV
2 Bolivia 25 M 2008 CCC (KI) and digestive involvement Yes 2008 273 79 000 None TDF, FTC, LPV/r
3 Bolivia 21 F 2009 Indeterminate stage Yes 2009 121 690 000 None TDF, FTC, DRV/r
4 Bolivia 38 F 2013 Indeterminate stage No 2013 174 120 000 Ileal histoplasmosis —
5 Ecuador 33 M 2010 Indeterminate stage Yes 2009 190 22 000 None TDF, FTC, EFV
6 Bolivia 38 M 2008 Digestive involvement Yes 2007 132 35 000 None TDF, FTC, EFV
7 Bolivia 31 M 2011 Indeterminate stage Yes 2008 81 110 000 Cerebral toxoplasmosis TDF, FTC, LPV/r
8 Bolivia 28 M 2008 CCC (KI) Yes 2006 341 — Pulmonary tuberculosis TDF, ABC, LPV/r
9 Spain 0 F 2009 Acute infection
(mother to child transmission)
Yes 2009 2934 330 000 None AZT, 3TC, NVP
10 Bolivia 36 F 2010 Indeterminate stage Yes 2007 300 — None TDF, FTC, NVP
11 Bolivia 31 F 2011 Indeterminate stage Yes 2009 91 250 000 Cerebral toxoplasmosis ABC, 3TC, DRV/r
12 Bolivia 37 M 2013 Digestive involvement Yes 2013 200 70 300 None TDF, FTC, EVG/COBI
Note: CD, Chagas disease; HIV, human immunodeﬁciency virus; HAART, highly active antiretroviral therapy; BZD, benznidazole; F, female; M, male; CCC (KI), chronic cardiac disease (Kuschnir stage I).
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TABLE 3. Epidemiological and clinical characteristics of patients with Chagas disease and organ transplantation
Patients
Country
of origin
Age
(years) Gender
Year of
diagnosis
of CD CD clinical stage
Treatment
with BZD
Year of organ
transplantation
Transplanted
organ Immunosuppressive therapy
21 Bolivia 34 M 2010 Digestive involvement No 1995 Kidney Corticosteroids, Azathioprine
22 Bolivia 40 F 2009 Indeterminate stage Yes 2010 Lung Corticosteroids, Tacrolimus,
Mycophenolate mofetil
23 Spain 63 M 2009 Acute infection acquired
through the organ transplantation
Yes 2009 Liver Corticosteroids, Tacrolimus,
Mycophenolate mofetil
24 Bolivia 40 M 2008 CCC (KI) Yes 2013 Kidney Corticosteroids, Tacrolimus
Note: BZD, benznidazole; CD, Chagas disease; F, female; M, male; CCC (KI), chronic cardiac disease (Kuschnir stage I).
CMI Salvador et al. Chagas disease and immunosuppression 857to a chorioamnionitis, and started treatment with benznidazole
and antiretroviral therapy soon after birth. Because of the
persistence of positive T. cruzi serology at the age of 4 years, she
received treatment with nifurtimox and is still under clinical and
serological follow up. Patient 23 was a 63-year-old man with
alcoholic liver cirrhosis and hepatocellular carcinoma, with
negative T. cruzi serology, who underwent liver transplantation
from a Paraguayan donor with Chagas disease, as previously
reported [13]. Benznidazole was administered for 60 days as
standard regimen after the transplantation. Although T. cruzi
PCR was always negative during follow up, serological tests
remained positive until 4 years after transplantation, hence
conﬁrming the transmission of the infection. Serological tests
are currently negative and liver function is preserved.
Twelve patients had HIV and Chagas disease co-infection.
Median baseline CD4+ cell count was 195 (81–2934) cells/
mm3, and 6 (50%) patients had <200 CD4+ cells/mm3 at the
moment of HIV infection diagnosis. Except for one patient, all of
them were receiving antiretroviral therapy when benznidazole
was administered; no unexpected adverse reaction was
described. From the eight patients with neoplastic diseases, ﬁve
women had gynaecological cancer and three patients had hae-
matological malignancies. Patients 18 and 20 had recently un-
dergone surgery and adjuvant chemotherapy had not yet been
administered. Patients with other immunosuppressive therapies
had a wide range of autoimmune and rheumatic diseases (see
Table 4).
Thirty-one patients received treatment with benznidazole, of
whom 17 (54.8%) presented some kind of adverse event: eleven
(35.5%) patients had pruritus, four (12.9%) patients presented
skin rash, three (9.7%) patients had nausea, three (9.7%) pa-
tients had headache, two (6.5%) patients had abdominal pain,
two (6.5%) presented elevated transaminase levels, one (3.2%)
patient had arthralgia, one (3.2%) patient presented neu-
tropenia, and one (3.2%) patient presented an anaphylactic
reaction. Treatment had to be withdrawn in four (12.9%) pa-
tients because of serious adverse events (skin toxicity and
anaphylaxis). Seven patients did not receive treatment with
benznidazole: ﬁve patients refused receiving treatment despiteClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologythe advice of the physician, and two patients were diagnosed
with Chagas disease close to the data collection and treatment
had not yet been offered.
Median time of follow up after Chagas disease diagnosis was
52 (1–94) months. One patient died during follow up: patient
14 was diagnosed with human T lymphotropic virus-associated
adult T-cell leukaemia/lymphoma and Chagas disease simulta-
neously, and died 1 year after diagnosis as the result of pro-
gression of the haematological malignancy. Apart from patient
23 (recipient of a liver transplant from a donor who was
seropositive for Chagas disease), no patient presented negative
T. cruzi serology during follow up. Nevertheless, T. cruzi PCR
could be performed in 23 patients after treatment, and it was
negative in all cases; median number of rt-PCR performed in
each patient was two (one to eight). Hence, no reactivation of
Chagas disease was diagnosed during follow up. Progression of
the cardiac or gastrointestinal involvement was observed in
only one patient; a right bundle branch block was detected in
patient 19 after 4 years of diagnosis and treatment, without any
clinical implication.DiscussionIn this study we describe clinical and epidemiological data of 38
patients with Chagas disease and any kind of immunosup-
pressive condition, corresponding to 2% of patients with
Chagas disease attending three centres of PROSICS during an
8-year period. This situation is increasingly being described in
endemic and non-endemic areas for Chagas disease, because
situations producing immunosuppression in the population
have increased in the last decades: e.g. new anti-neoplastic
treatments, increase of organ transplantation, new immuno-
suppressive drugs for immunological diseases [6,7]. However,
even though there was a high number of patients with
immunosuppression in our cohort of patients with Chagas
disease, none of them presented with either severe manifes-
tations or reactivation. Although the grades of immunosup-
pression in our cohort vary and a general conclusion is difﬁcultand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 854–860
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectto draw, our screening strategy and rapid treatment may
explain the absence of severe manifestations.
The control of T. cruzi infection relies mainly on the cellular
immune system. The host cellular immune response develops
2 months after primary infection, involving T helper type 1
(Th1), CD4+ and CD8+ lymphocytes and different cytokines
(interferon-γ, tumour necrosis factor-α and interleukin-12),
and is able to control the parasitaemia for a long time. An
imbalance in Th1 and Th2 lymphocytes may accelerate the
progression from the indeterminate form to the symptomatic
chronic form. Moreover, diseases and therapies that affect the
cellular immune response may disrupt this control and lead to
severe manifestations and high parasitaemia [1].
This situation has been observed mostly in HIV-infected
patients, especially in endemic countries, where the co-
infection rates ranges from 1.3% to 7.1% [14,15]. Reactivation
of Chagas disease in HIV-infected patients is considered an
AIDS-deﬁning condition in some endemic countries (Brazil),
and the risk of reactivation is increased when the CD4+
lymphocyte count is <200 cells/mm3. Central nervous system
involvement is present in 74% of reactivations (meningoen-
cephalitis, space-occupying lesions) and has high mortality;
myocarditis appears in up to 17% of the reactivations [16]. The
risk of Chagas disease reactivation in HIV-infected patients has
been evaluated in some studies performed in endemic coun-
tries, ranging from 15% to 20.8% [14,17]. Other opportunistic
infections affecting the brain such as toxoplasmosis, may pre-
sent with similar signs in neuroimaging studies [18]. In fact,
patient 7 in our study presented brain abscesses at the moment
of HIV diagnosis, with a CD4+ cell count of 81 cells/mm3, and
positive serological tests for T. cruzi and Toxoplasma gondii.
Although histological diagnosis could not be performed, benz-
nidazole and pyrimethamine/sulfadiazine were prescribed, with
complete resolution of the abscesses. In this patient, the aeti-
ology of the brain lesions remained unknown, hence Chagas
disease reactivation was not entirely ruled out. Case reports of
reactivation in co-infected patients in other organs (gastroin-
testinal tract, pericardium, peritoneum, skin and cervix) have
been described [19–22]. Being aware of Chagas disease reac-
tivation risk in HIV-infected patients, different groups have
published studies and consensus documents proposing
screening and early treatment strategies [16,23,24]. Secondary
prophylaxis with benznidazole (5 mg/kg/day, three times per
week) after reactivation has been proposed until reaching a
CD4+ cell count >200 cells/mm3 [23].
Information about the reactivation of Chagas disease in
transplanted patients mainly comes from kidney and heart
transplantation in countries where Chagas disease is endemic,
and clinical manifestations may include skin lesions (panniculitis,
erythema nodosum-like) [25,26]. Nevertheless, patients withious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 854–860
CMI Salvador et al. Chagas disease and immunosuppression 859Chagas disease increasingly participate in transplantation pro-
grammes because of the migration ﬂows from rural endemic
areas to urban areas and non-endemic areas; as a result, reac-
tivation and transmission of Chagas disease in non-endemic
areas due to organ transplantation has been described
[13,27]. Consequently, different expert groups have published
consensus documents to address these situations, stressing the
importance of screening for Chagas disease in donor and re-
cipients from endemic areas, offering early speciﬁc treatment,
and performing a close follow up with highly sensitive tests such
as PCR [28,29].
Published information about Chagas disease in patients with
neoplastic diseases is scarce. Reactivation of Chagas disease in
these patients is secondary to an immunosuppressive status due
to the tumour itself and/or to the anti-tumoral therapy
administered. A recent review of the literature in this area
published by Martínez-Pérez et al. retrieved only 12 cases of
Chagas disease in patients with neoplasia, and all but one of
them had haematological malignancies [7]. Conversely, in our
study, ﬁve of eight oncological patients had solid tumours.
Another issue to be addressed is the fact that Chagas disease
could induce neoplasia, because some observational studies
have reported a higher prevalence of oesophageal carcinoma
and uterine cervix leiomyoma in T. cruzi-infected populations;
however, no prospective studies have conﬁrmed this correla-
tion [30,31].
Corticosteroids and a wide range of immunosuppressive
therapies are used in the treatment of immunological disor-
ders. Only three cases of symptomatic reactivation of Chagas
disease in patients with autoimmune diseases have been
described: a patient with mesangial proliferative lupus
glomerulonephritis treated with corticosteroids and cyclo-
phosphamide who presented central nervous system involve-
ment and high parasitaemia, a patient with systemic lupus
erythematosus receiving cyclosporine and azathioprine who
developed a reactivation with cutaneous manifestations, and a
patient with rheumatoid arthritis receiving corticosteroids who
developed a polymyositis [32–34]. The low number of Chagas
disease and autoimmune disorder cases published corresponds
to systemic lupus erythematosus cases, except for two patients
with rheumatoid arthritis [6]. However, in our study, very
different autoimmune diseases have been described, including
not only systemic lupus erythematosus and rheumatoid
arthritis, but also autoimmune hepatitis, renal vasculitis or
Still’s disease.
This study has some limitations derived from its retrospec-
tive design. The information was retrieved from medical re-
cords, hence some data could have been missed. Management
and follow up of patients could be different depending on theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyphysicians’ criteria and the microbiological techniques available
in each centre.
As far as we know, the present study shows the largest cohort
of Chagas disease patients with an immunosuppressive condition
described in a non-endemic country. This condition has been
increasingly described, especially in non-endemic countries,
probably because of better health care access and stronger
immunosuppressive therapies available. The scarce information
published in this area comes from HIV-infected patients and
organ transplant recipients, and further experience in other
immunosuppressive conditions such as neoplastic and autoim-
mune diseases is required. Meanwhile, we highly recommend
offering screening tests in at risk populations before the immu-
nosuppression is established, early treatment with benznidazole,
and close follow up to prevent clinical reactivation.Transparency declarationThe authors have stated that there are no conﬂicts of interest in
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